Children and the Marshall Protocol

Children with a range of diseases and conditions can be treated with the Marshall Protocol (MP). There are more than a dozen in the study cohort who are doing well, and others who are being treated by family physicians, not regularly reporting. Benicar is approved by the FDA for use in children and adolescents 6 to 16 years of age.

Diagonostic tests used to confirm presence of Th1 inflammation in children are the same as those used for an adult: the D-metabolites. 1,25-D is helpful to estimate the bacterial load. The MP may also be used as a therapeutic probe to confirm Th1 inflammation.

When considering any treatment plan, the physician (and the patient) should weigh the risks versus the benefits. When compared to other protocols or medications that sick children are customarily given for Th1 inflammatory disease, the decision to go with the MP is usually self-evident. Physicians can find support for managing a child by posting in the MP Health Professionals Forum. Physicians may also directly contact Prof. Marshall by phone.

If a child is only mildly symptomatic and the parent is more concerned about preventing future health problems, it may be more difficult to find a supportive physician. On the other hand, children whose health problems are caught early seem to respond relatively quickly. As the disease process advances, several years of olmesartan may be essential for full recovery.

…..kids who are showing only early symptoms will probably not suffer as much from photosensitivityAbnormal sensitivity to sunlight and bright lights. Also referred to as "sun flare" or "light flare.", and most will not generate enough immunopathology for the symptoms to become a major issue.

Trevor Marshall, PhD

Olmesartan (Benicar) is a critical part of the MP. It not only activates the immune system, it also protects the body's organs.

The olmesartan (Benicar) dosage for a child should be considered on an individual basis, case by case. A simple weight ratio is often not helpful, as the distribution volume for the drug varies greatly with disease severity, even for people of a similar weight. A physician needs to consider symptoms, lab work and the level of 1,25-D when deciding on the optimal dosing for a child. More seriously ill children often need the same dose of Benicar as do some of the adults.

Daiichi Sankyo, Inc. announced in 2010 that the U.S. Food and Drug Administration (FDA) has approved the Benicar for use in children and adolescents 6 to 16 years of age. Benicar was originally approved in 2002 for the treatment of hypertension in adults. The FDA has set no dose at which Olmesartan is considered unsafe, in children or in adults.

Minocycline can optionally be added to the Olmesartan, just as with adults. Children should begin dose titration with 25mg of minocycline every other day, just as adults do. Our cohort experience determined that this is the optimum starting dose for both children and adults.

Minocycline can discolor developing teeth in children. This has been reported infrequently, and has been reversed by routine dental procedures.

The child's physician will probably want to utilize testing to monitor their MP patient closely.

A child will need to take the same light avoidance precautions as an adult. This may be problematic for the school-aged child who is not home-schooled. Teenagers who are concerned about appearance can now purchase attractive sunglasses from the recommended manufacturers. Opportunities for socialization and family fun will need to be scheduled indoors or between dusk and dawn.

In addition to those on the Marshall Protocol, both the very old and the very young benefit from shielding against emf

childrens health symposium-2016

It will be important to reduce 25-D in a child on the MP to below the therapeutic 12ng/ml threshold. An adequate intake of calcium will assist building a strong skeleton. Parents of a child on the MP must carefully supervise the child's diet to ensure compliance with MP dietary restrictions. Lack of dietary vitamin D does not cause rickets.

• Checklist for starting MP
• Familial aggregation of chronic diseases

<html> <div class=“patientinterviews”>

<html> <div class=“patientinterviewboxl”> <div class=“patientinterviewimage”></html><html></div> <div class=“patientinterviewtext”> <div class=“patientinterviewname”></html>Doreen V. (patient's mother)<html></div></html>

autism, ADHD, depression, severe anxiety, chronic fatigue syndrome (CFS)

Read the interview

<html></div></div></html>

<html> <div class=“patientinterviewboxr”>

<div class=“patientinterviewimage”></html><html></div> <div class=“patientinterviewtext”> <div class=“patientinterviewname”></html>Robyn Russell (patient's mother)<html></div></html>

Lyme, myoclonus

Read the interview

<html></div></div>

<br clear=“left” />

</div> </html>

Interviews of patients with other diseases are also available.